Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q3 2019 · 10-Q
Revenue$312.00K$312.00K−20.0% vs Q3 2018 Net Income-$1.87M-$1.87MN/M vs Q3 2018 EPS Diluted-$0.03-$0.03N/M vs Q3 2018 Operating Income-$912,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$831,000N/M Margins · derivedOperating margin-292.3%+146.4 pt vs Q3 2018
Net margin-600.3%−166.5 pt vs Q3 2018
ended Apr 30, 2019 · filed Jun 13, 2019 · 44 d after period end